Antibody affinity can be a decisive factor in Type 1 diabetes in adults

As per the studies conducted at Helmholtz Zentrum Munchen and published in Diabetes Care states that the high-affinity glutamic acid decarboxylase (GAD) antibodies are found in patients who can produce limited insulin on their own insulin and further these patients will require insulin therapy in a short time. They can distinguish as adult patients suffering from autoimmune type 1 diabetes can be differentiated from patients with non-autoimmune type 2 diabetes through GAD. As per the further research the progression of this problem is quite slow. It does not appear until the age of 30 and the patients does not need insulin therapy in the beginning but with the progression they require insulin along with medicines. One of the c-researcher, Dr. Peter Achenbach, Stephanie Krause explains, “Our findings show that the GAD antibody affinity is a valuable new diagnostic marker in LADA patients. As with childhood type 1 diabetes, we can forecast the progression of the disease and adapt the therapeutic measures accordingly. The antibody affinity should now also be taken into consideration in clinical studies involving LADA patients.”